Precision cardiovascular risk prediction in type 1 diabetes: An IMI2 SOPHIA analysis
Cardiovascular disease (CVD) is a major long-term complication and the leading cause of morbidity and mortality among individuals with type 1 diabetes (T1D), with a substantially higher prevalence compared to the general population and driven by multiple interrelated risk factors-underscoring the urgent need for accurate risk assessment. To support more tailored approaches to CVD prevention, recently, five discordant phenotypic risk profiles for CVD were identified in the general population in Europe with diverse relationship between body mass index and cardiometabolic biomarkers. Here, we show their applicability in 44,212 people with T1D. Improved glycemic control was linked to a decrease in CVD risk as people with T1D with lower glycated hemoglobin belonged to the baseline concordant cluster. This supports the contention that glycemic control in people with T1D is an integral part of lowering CVD risk.
Authors
- Birgit Reinhart-Steininger
- Jordi Blanch (ORCID: https://orcid.org/0000-0001-8211-3292)
- Nicole Forestier
- Naichuan Zhang
- Nele Steenackers (ORCID: https://orcid.org/0000-0003-4611-4962)
- Paul W. Franks (ORCID: https://orcid.org/0000-0002-0520-7604)
- Ditte F. Heidemann (ORCID: https://orcid.org/0000-0003-4315-5793)
- Stefanie Schmid
- Sofia Pazmiño (ORCID: https://orcid.org/0000-0001-8579-6914)
- Daniel Coral (ORCID: https://orcid.org/0000-0002-8809-4544)
- Carmen Hurtado del Pozo (ORCID: https://orcid.org/0000-0003-4379-0041)
- Yenny Leal (ORCID: https://orcid.org/0000-0003-1926-1844)
- Bart Van der Schueren (ORCID: https://orcid.org/0000-0003-4754-784X)
- José Manuel Fernández‐Real (ORCID: https://orcid.org/0000-0002-7442-9323)
- Christian-Dominik Möller
- Laura Gallardo‐Nuell
- Shreekar Bharadwaj Araveti
- Jonathan Rosen (ORCID: https://orcid.org/0009-0001-4409-7110)
- Carel W. le Roux (ORCID: https://orcid.org/0000-0001-5521-5445)
- Stefanie Lanzinger
- Amar van Laar (ORCID: https://orcid.org/0000-0003-1289-0955)
- Rafael Ramos
- Chantal Mathieu
- Kinga Nowak (ORCID: https://orcid.org/0009-0003-0517-5344)
Institutions
- University College Dublin (IE)
- Queen Mary University of London (GB)
- Lund University (SE)
- Novo Nordisk (Denmark) (DK)
- Universität Ulm (DE)
- Universitat de Girona (ES)
- Instituto de Salud Carlos III (ES)
- Maastricht University (NL)
- Bürgerhospital Frankfurt am Main (DE)
- Departament de Salut (ES)
- Breakthrough (US)
- Zimmer Biomet (Germany) (DE)
- Red de Investigación en Actividades Preventivas y Promoción de la Salud (ES)
- Institut d'Investigació Biomèdica de Girona (ES)
- Institut Universitari d'Investigació en Atenció Primària Jordi Gol (ES)
- Schön Klinik Bad Aibling (DE)
- Deutsches Diabetes-Zentrum e.V. (DE)
- Institut Català de la Salut (ES)
- Hospital Universitari de Girona Doctor Josep Trueta (ES)
- German Center for Diabetes Research (DE)
- Heinrich Heine University Düsseldorf (DE)
- Medical University of Vienna (AT)
- KU Leuven (BE)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-04-16
- DOI
- https://doi.org/10.1038/s41467-026-72029-z
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Federation of Pharmaceutical Industries and Associations
- European Commission